Institution statistics

ASTRAZENECA AB - Sweden 

Ranking results:

Past rankings:
2018
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:900-1000
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:400-500
Total Number of Projects:600-700
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:800-900
Total Number of Projects:800-900
Networking Rank (Reputation):> 1000
Partner Constancy:500-600
Project Leadership Index:500-600
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2013
Criterium:Position:
Overall Score:600-700
Total Project Funding:500-600
Total Project Funding per Partner:400-500
Total Number of Projects:68
Partner Constancy:51
Project Leadership Index:69
Diversity Index:64
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:70
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
2011
Criterium:Position:
Overall Score:800-900
Total Project Funding:900-1000
Total Project Funding per Partner:800-900
Total Number of Projects:900-1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:400-500
2010
Criterium:Position:
Overall Score:700-800
Total Project Funding:500-600
Total Project Funding per Partner:600-700
Total Number of Projects:800-900
Networking Rank (Reputation):700-800
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:500-600
2009
Criterium:Position:
Overall Score:800-900
Total Project Funding:500-600
Total Project Funding per Partner:600-700
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:800-900
2008
Criterium:Position:
Overall Score:600-700
Total Project Funding:300-400
Total Project Funding per Partner:400-500
Total Number of Projects:500-600
Networking Rank (Reputation):500-600
Partner Constancy:400-500
Project Leadership Index:> 1000
Diversity Index:200-300
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 58
As coordinator: 1
As participant: 57
Sole participant: 0
Coordinator / Participant Ratio: 0.02*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 4.017.848 281.983 1
2019 0 126.323.350 1.776.193 12
2018 0 34.105.743 0 3
2017 0 66.648.068 527.319 7
2016 0 35.741.579 1.977.445 8
2015 0 10.088.161 666.784 3
2014 0 3.301.294 232.272 1
2013 0 21.428.778 2.163.015 6
2012 0 4.165.299 202.078 1
2011 0 8.609.001 473.035 2
2010 0 5.791.918 364.670 2
2008 0 30.774.393 1.984.363 5
2006 0 17.220.107 1.011.256 3
2005 0 11.998.527 285.679 1
2004 0 4.850.000 285.294 1
2001 1.555.000 1.411.000 529.850 1 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
JANSSEN PHARMACEUTICA NV14
NOVARTIS PHARMA13
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD11
PFIZER LIMITED10
BAYER AKTIENGESELLSCHAFT9
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE9
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM9
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT9
ELI LILLY AND COMPANY LIMITED7
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT7
KAROLINSKA INSTITUTE7
UCB BIOPHARMA SPRL7
UNIVERSITAIR MEDISCH CENTRUM UTRECHT7
BOEHRINGER INGELHEIM INTERNATIONALGMBH6
CHARITE UNIVERSITAETSMEDIZIN BERLIN6
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH6
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE6
KATHOLIEKE UNIVERSITEIT LEUVEN6
SANOFIAVENTIS DEUTSCHLAND6
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL6
TAKEDA DEVELOPMENT CENTRE EUROPE6
UPPSALA UNIVERSITET6
F HOFFMANNLA ROCHE5
FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM5
GOETEBORGS UNIVERSITET5
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE5
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV5
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV5
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN5
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE5
THE UNIVERSITY OF MANCHESTER5
UNIVERSITAET BERN5
UNIVERSITY OF NEWCASTLE UPON TYNE5
ACADEMISCH ZIEKENHUIS GRONINGEN4
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE4
KING'S COLLEGE LONDON4
STICHTING LYGATURE4
THE UNIVERSITY OF SHEFFIELD4
UNIVERSITA DEGLI STUDI DI MILANO4
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN4
UNIVERSITY OF COPENHAGEN4
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM3
ACADEMISCH ZIEKENHUIS LEIDEN3
ALLERGAN LIMITED3
AMGEN LIMITED3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
EUROPEAN PATIENTS' FORUM3
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV3
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT3
HEINRICHHEINEUNIVERSITAET DUESSELDORF3
KAROLINSKA INSTITUTET3
MEDIZINISCHE UNIVERSITAET WIEN3
NOVO NORDISK3
REGION HOVEDSTADEN3
RIJKSUNIVERSITEIT GRONINGEN3
STICHTING VUMC3
STOCKHOLMS UNIVERSITET3
TEVA PHARMACEUTICAL INDUSTRIES LIMITED3
UNIVERSIDADE DE AVEIRO3
UNIVERSITAETSKLINIKUM FREIBURG3
UNIVERSITAT WIEN3
UNIVERSITE VICTOR SEGALEN BORDEAUX II3
UNIVERSITEIT LEIDEN3
UNIVERSITEIT UTRECHT3
UNIVERSITY COLLEGE LONDON3
UNIVERSITY OF DUNDEE3
UNIVERSITY OF LEEDS3
UNIWERSYTET JAGIELLONSKI3
AARHUS UNIVERSITETSHOSPITAL2
ABBVIE DEUTSCHLAND GMBH & CO KG2
ABBVIE INC2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
ASTELLAS PHARMA EUROPE BV2
BAYER PHARMA2
CELLARTIS AB2
CERTARA UK LIMITED2
CHALMERS TEKNISKA HOEGSKOLA AB2
CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL2
CLINIQUES UNIVERSITAIRES SAINTLUC2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS2
CUSTODIX NV2
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV2
EUROPEAN SYNCHROTRON RADIATION FACILITY2
FUNDACIO IMIM2
GIOTTO BIOTECH2
GLAXOSMITHKLINE BIOLOGICALS2
GRUNENTHAL2
INSTITUT DE RECHERCHES SERVIER2
INSTITUT PASTEUR2
INTERNATIONAL ALLIANCE OF PATIENT'ORGANIZATIONS2
IXSCIENT LIMITED2
KUNGLIGA TEKNISKA HOEGSKOLAN2
LEAD DISCOVERY CENTER2
LEIDEN UNIVERSITY MEDICAL CENTER2
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE2
MERCK SHARP & DOHME CORP2
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE2
NORGES TEKNISKNATURVITENSKAPELIGE UNIVERSITET NTNU2
Constancy:

Total number of partners:946

Partner loyalty:
Frequent Partner: (> 2 projects): 346
Rare Partner: 600

Frequent / Rare Partner Ratio: 0.58

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES18
RTD HORIZONTAL TOPICS9
SOCIAL AND ECONOMIC CONCERNS8
INDUSTRY AND TECHNOLOGY8
PROTECTING MAN AND HIS ENVIRON1

Project overview:

Start dateProjectacronymrolefundingpartners
2020-01-01Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery TrainCKDisparticipant4.017.84810
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95336
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19269
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99831
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-05-01Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug PD-MINDparticipant999.69810
2019-05-01INnate-ImmunomeTabolIsm as Antiviral TargEt INITIATEparticipant4.054.10614
2019-05-01Saracatinib Trial tO Prevent FOP STOPFOPparticipant999.7106
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89734
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-03-01A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies V.A. Cureparticipant3.792.13617
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2019-01-01Stirling heat pump for high temperature industrial use Highliftparticipant2.439.5123
2018-12-01European Screening Centre; Unique Library for Attractive Biology ESCulabparticipant18.249.99320
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-06-01The GetReal Initiative GetReal Initiativeparticipant1.750.00016
2017-11-01Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections COMBACTE-CDIparticipant2.312.30514
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88154
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-09-01Improving Genome Editing Efficiency (IMGENE) IMGENEparticipant2.068.4097
2017-01-01Molecular Tools for Nucleic Acid Manipulation for Biological Intervention MMBioparticipant3.971.34819
2017-01-01REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 RESCEUparticipant14.498.12518
2017-01-01Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 TransQSTparticipant8.000.00023
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-06-01PET Imaging in Drug Design and Development PET3Dparticipant3.901.24810
2016-02-01Targeted small-molecule Stabilisation of Protein-Protein Interactions TASPPIparticipant3.342.32312
2016-01-01ISOTOPIC LABELING FOR DRUG INNOVATION ISOTOPICSparticipant3.948.84413
2016-01-01Non-Noble Metal Catalysis - NoNoMeCat NoNoMeCatparticipant3.318.63415
2016-01-01Big Data in Chemistry BIGCHEMparticipant2.555.5349
2016-01-01Accelerated Early staGe drug diScovery AEGISparticipant3.836.99626
2015-11-01Synaptic Dysfunction in Alzheimer Disease SyDADparticipant3.846.73611
2015-09-01Exascale Compound Activity Prediction Engine ExCAPEparticipant3.910.1409
2015-01-01Advanced XFEL and Synchrotron based Probes of Protein Structure and Dynamics X-probeparticipant2.331.2859
2014-03-01"FLUOR21 : Synthesis, structure and function of fluorinated systems" FLUOR21participant3.301.2949
2013-10-01Phylogenetic exploration of medicinal plant diversity MEDPLANTparticipant4.231.60510
2013-10-01Female Investigators in Nonlinear Optical Nanoscopy - FINON FINONparticipant3.470.6526
2013-10-01Identification and validation of novel pharmaceutical drug targets for cardiovascular disease CARTARDISparticipant5.973.52113
2013-01-01Innovative Modelling for Pharmacological Advances through Collaborative Training IMPACTparticipant1.467.9582
2013-01-01Pushing the Envelope of Nuclear Magnetic Resonance Spectroscopy for Paramagnetic Systems. A Combined Experimental and Theoretical Approach PNMRparticipant3.470.41312
2013-01-01Membrane Protein Nanocrystallography NANOMEMparticipant2.814.62910
2012-01-01Development of Cytochrome P450 Enzymes for the Chemical Manufacturing Industries P4FIFTYparticipant4.165.29910
2011-03-01Integrating research training in particle & powder technology to deliver efficient products with high functionality PowTechparticipant3.909.00115
2011-01-01Stem Cells for Relevant Efficient Extended and Normalized Toxicology SCR&TOXparticipant4.700.00015
2010-11-01Pulmonary Imaging Network π-netparticipant3.043.59910
2010-01-01Arrhythmogenic potential of drugs ARITMOparticipant2.748.31920
2008-06-01Integrated synthesis and purification of single enantiomers INTENANTparticipant3.693.40011
2008-04-01Large Scale Semantic Computing\nSemantic Web technologies\ndistributed reasoning\nprobabilistic reasoning\nweb-scale inference\ninformation retrieval LarKCparticipant7.703.29319
2008-02-01European drug initiative on channels and transporters EDICTparticipant11.896.55728
2008-02-01Exploring and understanding adverse drug reactions by integrative mining of clinical records and biomedical knowledge EU-ADRparticipant4.500.00014

overview shows latest 50 from 58 projects (2000-01-01 - 2020-12-31)
A full list of projects can be found here:

Alias institution names:
  • ASTRAZENECA AB

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum